Zippel, Douglas Yalon, Tal Nevo, Yehonatan Markel, Gal Asher, Nethanel Schachter, Jacob Goitein, David Segal, Tamar Abramovich Nissan, Aviram Hazzan, David
...
Published in
American journal of surgery
Minimally invasive adrenalectomy has facilitated resection of resistant adrenal metastases. The adrenal gland may function as a sanctuary site for metastatic growth despite systemic therapy. The objective of the study was to assess the outcomes of selective minimally invasive adrenalectomy during immunotherapy. Candidates included patients with adr...
Li, Depei Duan, Hao Jiang, Pingping Jiang, Xiaobing He, Zhenqiang Guo, Chengcheng Mou, Yonggao
Published in
American journal of translational research
The approval of immune checkpoint inhibitors (ICI) for metastatic melanoma in 2011 has changed the treatment landscape of this disease. However, current trend of the population-based survival remains unclear. 8078 patients with metastatic melanoma diagnosed in the pre-ICI (2005-2010) and post-ICI period (2011-2016) were enrolled from the Surveillan...
O'Neill, Conor H McMasters, Kelly M Egger, Michael E
Published in
Surgical oncology clinics of North America
Stage IV melanoma has a 5-year survival rate of 6%, but considerable advances have been made in systemic therapies. Systemic immunotherapy has achieved durable responses in up to 40% of patients, with similar improvements with targeted therapies. This has reshaped the landscape for surgery in stage IV melanoma. Metastasectomy can be considered in p...
Gingrich, Alicia A Kirane, Amanda R
Published in
Surgical oncology clinics of North America
Clinical outcomes for metastatic melanoma have been dramatically altered by recent developments in immunotherapy and targeted strategies, but response to these therapies is not uniform, the majority of patients do not respond, and clinical response can be self-limited. Current directions in melanoma treatment aim to leverage a combination of therap...
Farrow, Norma E. Turner, Megan C. Salama, April K. S. Beasley, Georgia M.
Published in
Oncology and Therapy
Introduction Since 2011, encouraging clinical trial results have led to approval of multiple new therapies for advanced melanoma, but the impact of these therapies outside of trial populations is largely unknown. This study examines use of novel therapies and survival in contemporary patients with melanoma. Methods Stage I–IV melanoma patients were...
Rouanet, Jacques Benboubker, Valentin Akil, Hussein Hennino, Ana Auzeloux, Philippe Besse, Sophie Pereira, Bruno Delorme, Solène Mansard, Sandrine D'Incan, Michel
...
In line with the ongoing phase I trial (NCT03784625) dedicated to melanoma targeted radionuclide therapy (TRT), we explore the interplay between immune system and the melanin ligand [131I]ICF01012 alone or combined with immunotherapy (immune checkpoint inhibitors, ICI) in preclinical models. Here we demonstrate that [131I]ICF01012 induces immunogen...
Lin, Jingrong Xue, Minmin Gao, Mingyang Yu, Pu Han, Shixin
Published in
Dermatology and Therapy
Toripalimab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1). It has recently been approved as an immune checkpoint inhibitor in second-line therapies in patients with unresectable or metastatic melanoma; however, it may be associated with various immune-related adverse events (irAEs). Here we report a case of toripalimab-i...
Ali, Arwa Dumbrava, Monica Riddell, Kylie Stewart, Nina Ward, Robyn Ibrahim, Ahmed K. Chin, Melvin
Published in
BMC Cancer
BackgroundPlanar-based measurements of lesions in metastatic melanoma have limitations in estimating tumor burden of a patient and in predicting response to treatment. Volumetric imaging might add predictive value to Response criteria in Solid Tumor (RECIST)-measurement. Based on clinical observations, we explored the association between baseline t...
Nistor, Gabriel I. Dillman, Robert O.
Published in
Journal of Translational Medicine
BackgroundIn a randomized phase II trial conducted in patients with metastatic melanoma, patient-specific autologous dendritic cell vaccines (DCV) were associated with longer survival than autologous tumor cell vaccines (TCV). Both vaccines presented antigens from cell-renewing autologous tumor cells. The current analysis was performed to better un...
Proboka, Guna Tilgase, Andra Isajevs, Sergejs Zablocka, Tatjana Olmane, Evija Rasa, Agnija Alberts, Pēteris
Published in
Case Reports in Oncology
Adrenal gland melanoma is an extremely rare diagnosis with less than 20 cases reported. The criteria for diagnosing adrenal gland melanoma include involvement of only one adrenal gland, presence of melanin pigment in the histological examination of the tumor tissue, no primary melanoma tumor in any other organ, and no history of resection of pigmen...
